Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: A link among platelet activation, angiogenesis, and thrombosis?

Chest

Volumn 132, Issue 6, 2007, Pages 1913-1919

  Choudhury, Anirban ^a   Freestone, Bethan ^a   Patel, Jeetesh ^a   Lip, Gregory Y H ^a,b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Atrial fibrillation; Platelet activation; Soluble CD40 ligand; Tissue factor

Indexed keywords

ANGIOPOIETIN; CD40 LIGAND; THROMBOPLASTIN; VASCULOTROPIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD CLOTTING; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUS RHYTHM; THROMBOCYTE ACTIVATION; THROMBOGENICITY;

EID: 37549012557     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-1565     Document Type: Article

References (46)

1. Lip GYH, Boos CJ. Antithrombotic treatment in atrial fibrillation. Heart 2006; 92:155-161
2. Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346:1313-1314
3. Feinberg WM, Pearce LA, Hart RG, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999; 30:2547-2553
4. Gustafsson C, Blomback M, Britton M, et al. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21:47-51
5. Lip GY, Lip PL, Zarifis J, et al. Fibrin d-dimer and β- thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94:425-431
6. Minamino T, Kitakaze M, Sanada S, et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation 1998; 98:1721-1727
7. Yamauchi K, Furui H, Taniguchi N, et al. Plasma β-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation. Jpn Heart J 1986; 27:481-487
8. Furui H, Taniguchi N, Yamauchi K, et al. Effects of treadmill exercise on platelet function, blood coagulability and fibrinolytic activity in patients with atrial fibrillation. Jpn Heart J 1987; 28:177-184
9. Heppell RM, Berkin KE, McLenachan JM, et al. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997; 77:407-411
10. Conway DSG, Pearce LA, Chin BSP, et al. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with non-valvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 106:1962-1967
11. Caine GJ, Lip GY, Stonelake PS, et al. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004; 92:185-190
12. O'Brien ER, Garvin MR, Dev R, et al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994; 145:883-894
13. Babiak A, Schumm AM, Wangler C, et al. Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion. Cardiovasc Res 2004; 61:789-795
14. Blann AD, Belgore FM, McCollum CN, et al. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes. Clin Sci (Lond) 2002; 102:187-194
15. Chung N, Belgore F, Li-Saw-Hee FL, et al. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke 2002; 33:2187-2191
16. Freestone B, Chong AY, Lim HS, et al. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? Ann Med 2005; 37:1-8
17. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172:1535-1545
18. Blum S, Issbruker I, Willuweit A, et al. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem 2001; 276:33428-33434
19. Morrissey JH. Tissue factor: an enzyme cofactor and true receptor. Thromb Haemost 2001; 86:66-74
20. Seko Y, Nishimura H, Takahashi N, et al. Serum levels of vascular endothelial growth factor and transforming growth factor-b1 in patients with patients with atrial fibrillation undergoing defibrillation therapy. Jpn Heart J 2000; 41:27-32
21. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001; 2:667-673
22. Anand SX, Viles-Gonzalez JF, Badimon JJ, et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90:377-384
23. Slupsky JR, Kalbas M, Willuweit A, et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998; 80:1008-1014
24. Zhou L, Stordeur P, de Lavareille A, et al. CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost 1998; 79:1025-1028
25. Blann AD, Tan KT, Tayebjee MH, et al. Soluble CD40L in peripheral artery disease: relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 2005; 93:578-583
26. Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type-2 diabetes and coronary artery disease. Circulation 2003; 107:1954-1957
27. Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003; 107:2664-2669
28. Blake GJ, Ostfeld RJ, Yucel EK, et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high resolution MRI. Arterioscler Thromb Vasc Biol 2003; 23:e11-e14
29. Patel JV, Lim HS, Nadar S, et al. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens 2006; 24:117-121
30. Garlichs CD, Kozina S, Fateh-Moghadam S, et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003; 34:1412-1418
31. Heeschen C, Dimmeler S, Hamm C, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348:1104-1111
32. Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104:2266-2268
33. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16:111-135
34. Henn V, Steinbach S, Buchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporarily limited by coexpressed CD40. Blood 2001; 98:1047-1054
35. Webb NJ, Bottomley MJ, Watson CJ, et al. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci 1998; 94:395-404
36. Reinders ME, Sho M, Robertson SW, et al. Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol 2003; 171:1534-1541
37. Manchin D, Campbell M. Statistical tables for the design of clinical trials. Oxford, UK: Blackwell Scientific, 1987
38. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the Tie2 receptor by secretion-trap expression cloning. Cell 1996; 87:11161-11169
39. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that interrupts in-vivo angiogenesis. Science 1997; 277:55-60
40. Makin AJ, Chung NAY, Silverman SL, et al. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci 2003; 104:397-404
41. Nishino M, Hoshida S, Tanouchi J, et al. Time to recover from atrial hormonal, mechanical, and electrical dysfunction after successful electrical cardioversion of persistent atrial fibrillation. Am J Cardiol 2000; 85:1451-1454
42. Pedram A, Razandi M, Levin ER. Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis. Endocrinology 2001; 142:1578-1586
43. Lip GYH, Patel JV, Hughes E, et al. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007; 38:1229-1237
44. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003; 107:1123-1128
45. Ueland T, Aukrust P, Yndestad A, et al. Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 2005; 26:1101-1107
46. Lim HS, Blann AD, Lip GYH. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationship to cardiovascular disease and risk factor intervention. Circulation 2004; 109:2524-2528